{"title":"Neoadjuvant Chemotherapy in Resectable Biliary Tract Cancer: A Systematic Review and Metanalysis.","authors":"Rafael Alvim Pereira, Gabriel Barcellos, Gabriel Lenz, Allan Andresson Lima Pereira, Tiago Biachi de Castria","doi":"10.1002/jso.70169","DOIUrl":"https://doi.org/10.1002/jso.70169","url":null,"abstract":"<p><strong>Background and objectives: </strong>The benefit of neoadjuvant chemotherapy in resectable biliary tract cancer remains unclear.</p><p><strong>Methods: </strong>A systematic review and meta-analysis of 23 studies (n = 11,344) compared neoadjuvant chemotherapy with upfront surgery.</p><p><strong>Results: </strong>Neoadjuvant therapy improved overall survival (HR = 0.69) and R0 resection rates (OR = 1.30) without increasing postoperative morbidity or mortality.</p><p><strong>Conclusions: </strong>Neoadjuvant chemotherapy may improve survival and surgical outcomes in resectable biliary tract cancer.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benedikt Niedermaier, Nabil Khan, Florian Eichhorn, Maria Zehentmeier, Heidrun Grosch, Raffaella Griffo, Alessio Campisi, Antonia Margineanu, Michael Allgäuer, Petros Christopoulos, Michael Thomas, Hauke Winter, Martin E Eichhorn
Background and objectives: Robot-assisted thoracoscopy (RATS) is rapidly emerging as the preferred approach for the resection of thymic epithelial tumors (TET). Current challenges include the role of RATS in locally advanced disease and combined additional resections.
Methods: This single-center study included all consecutive robot-assisted surgeries for TET performed between 2018 and 2024. We report perioperative outcomes and findings from a large center for robotic surgery center.
Results: One hundred and forty-three patients underwent RATS for the resection of histologically confirmed TET, including 130 (91%) patients with thymoma and 13 (9%) patients with thymic carcinoma. The median tumor size was 54 mm (35.5-75) and most patients presented in a localized stage of disease, with 120 patients (83.9%) in TNM stage I (TNM 8th edition). The conversion rate to open surgery was 4.2% and R0 resection was achieved in 134 (93.7%) patients. Combined extended resections that included lung, pericardium or great vessels were performed in 44 (30.8%) patients and were the only independent predictor of postoperative complications in a multivariable logistic regression model (OR 2.87; p = 0.03).
Conclusions: Robot-assisted surgery is feasible and without unexpected safety concerns for TET. Combined extended resections, often necessary for locally advanced disease, are a significant predictor of postoperative complications.
背景和目的:机器人辅助胸腔镜(RATS)正迅速成为胸腺上皮肿瘤(TET)切除术的首选方法。目前的挑战包括大鼠在局部晚期疾病中的作用和联合额外切除。方法:这项单中心研究包括2018年至2024年期间进行的所有连续的TET机器人辅助手术。我们报告一个大型机器人手术中心的围手术期结果和发现。结果:143例经组织学证实的TET患者行大鼠切除术,其中胸腺瘤130例(91%),胸腺癌13例(9%)。肿瘤中位大小为54 mm(35.5-75),大多数患者表现为局部分期,其中120例(83.9%)患者为TNM I期(TNM第8版)。开腹转换率为4.2%,134例(93.7%)患者完成R0切除术。在多变量logistic回归模型中,44例(30.8%)患者进行了包括肺、心包或大血管在内的联合扩展切除,这是术后并发症的唯一独立预测因素(or 2.87; p = 0.03)。结论:机器人辅助手术是可行的,并且没有意外的安全问题。联合扩大切除,通常是局部晚期疾病所必需的,是术后并发症的重要预测因素。
{"title":"Impact of Combined Additional Resections on the Surgical Outcomes of Robot-Assisted Resection of Thymic Epithelial Tumors.","authors":"Benedikt Niedermaier, Nabil Khan, Florian Eichhorn, Maria Zehentmeier, Heidrun Grosch, Raffaella Griffo, Alessio Campisi, Antonia Margineanu, Michael Allgäuer, Petros Christopoulos, Michael Thomas, Hauke Winter, Martin E Eichhorn","doi":"10.1002/jso.70162","DOIUrl":"https://doi.org/10.1002/jso.70162","url":null,"abstract":"<p><strong>Background and objectives: </strong>Robot-assisted thoracoscopy (RATS) is rapidly emerging as the preferred approach for the resection of thymic epithelial tumors (TET). Current challenges include the role of RATS in locally advanced disease and combined additional resections.</p><p><strong>Methods: </strong>This single-center study included all consecutive robot-assisted surgeries for TET performed between 2018 and 2024. We report perioperative outcomes and findings from a large center for robotic surgery center.</p><p><strong>Results: </strong>One hundred and forty-three patients underwent RATS for the resection of histologically confirmed TET, including 130 (91%) patients with thymoma and 13 (9%) patients with thymic carcinoma. The median tumor size was 54 mm (35.5-75) and most patients presented in a localized stage of disease, with 120 patients (83.9%) in TNM stage I (TNM 8th edition). The conversion rate to open surgery was 4.2% and R0 resection was achieved in 134 (93.7%) patients. Combined extended resections that included lung, pericardium or great vessels were performed in 44 (30.8%) patients and were the only independent predictor of postoperative complications in a multivariable logistic regression model (OR 2.87; p = 0.03).</p><p><strong>Conclusions: </strong>Robot-assisted surgery is feasible and without unexpected safety concerns for TET. Combined extended resections, often necessary for locally advanced disease, are a significant predictor of postoperative complications.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: There remains uncertainty regarding whether the determination of a safe margin is the responsibility of the surgeon or the pathologist during the pathological analysis of tissue from various procedures. This study aims to assess the alterations in surgical margin dimensions of tissue 1 h post-excision, following 24 h of formalin fixation, and pathological in comparison to the margin determined prior to excision.
Patients and methods: Measurements and mean values were taken for each specimen at four stages: before excision, 1 h post-excision, after 24 h of 10% formalin fixation, and following pathologic examination. BCCs and SCCs were evaluated independently, and statistical analyses were performed to assess changes in the measurements of the specimens.
Results: Table 1 illustrates highly significant reductions of the order of 70%-80% overall in the measured specimen margin widths over time for all of the categories measured.
Conclusion: Excised skin cancers were found to undergo significant shrinkage at every stage of pathological evaluation, resulting in a surgical margin significantly narrower than the safety margin initially determined. We have clarified what the surgical margin reported by the dermatopathologist actually means. In this way, it was aimed to eliminate the disagreement between the surgeon and the pathologist and to prevent the need for additional surgery and morbidities.
{"title":"Examining Surgical Margins in the Excision of Basal Cell Carcinoma and Squamous Cell Carcinoma: Evaluating Pre-Excision, Post-Excision, Post-Fixation, and Pathological Margin Measurements.","authors":"Özgür Agdoğan, Ayşegül İsal Arslan","doi":"10.1002/jso.70163","DOIUrl":"https://doi.org/10.1002/jso.70163","url":null,"abstract":"<p><strong>Introduction: </strong>There remains uncertainty regarding whether the determination of a safe margin is the responsibility of the surgeon or the pathologist during the pathological analysis of tissue from various procedures. This study aims to assess the alterations in surgical margin dimensions of tissue 1 h post-excision, following 24 h of formalin fixation, and pathological in comparison to the margin determined prior to excision.</p><p><strong>Patients and methods: </strong>Measurements and mean values were taken for each specimen at four stages: before excision, 1 h post-excision, after 24 h of 10% formalin fixation, and following pathologic examination. BCCs and SCCs were evaluated independently, and statistical analyses were performed to assess changes in the measurements of the specimens.</p><p><strong>Results: </strong>Table 1 illustrates highly significant reductions of the order of 70%-80% overall in the measured specimen margin widths over time for all of the categories measured.</p><p><strong>Conclusion: </strong>Excised skin cancers were found to undergo significant shrinkage at every stage of pathological evaluation, resulting in a surgical margin significantly narrower than the safety margin initially determined. We have clarified what the surgical margin reported by the dermatopathologist actually means. In this way, it was aimed to eliminate the disagreement between the surgeon and the pathologist and to prevent the need for additional surgery and morbidities.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aimée Galatas, Hannah R Malinosky, Andrew G Chapple, Sydney McManus, Ann Byerley, Ethan Littlefield, Sarah Hemelt, John Lyons, Denise Danos, Omeed Moaven
Background: This study aims to evaluate potential disparities in multimodal treatment and its impact on outcomes among pancreatic cancer patients in Louisiana.
Methods: Data on pancreatic cancer cases diagnosed between 2000 and 2020 were obtained from the Louisiana Tumor Registry. Bivariate relationships were assessed via Chi-square tests. Treatment was modeled with logistic regression models. Time-to-treatment was modeled with negative binomial regression models. Overall survival was analyzed with Cox proportional hazards models. Results are reported as odds ratio (OR), rate ratios (RR), hazards ratio (HR), and 95% Wald confidence intervals.
Results: A total of 8,466 patients with pancreatic cancer were included. A significantly higher proportion of nonmetastatic cases received therapy compared to metastatic cases. Non-Hispanic Black patients with nonmetastatic disease experienced a significantly longer time to treatment compared to Non-Hispanic White patients. In the metastatic model, uninsured patients and those with Medicaid had the highest odds of not receiving therapy. Primary resection was a strong predictor of improved survival. Nonsurgical therapy also contributed to better outcomes.
Conclusion: The findings of this study are instrumental in designing a more granular investigation of multi-level determinants to identify the actionable items driving the observed disparities associated with worse outcomes.
{"title":"Multimodal Care and Outcomes of Pancreatic Cancer Patients Are Influenced by Factors Beyond Biology: A Population-Based Study From Louisiana Tumor Registry.","authors":"Aimée Galatas, Hannah R Malinosky, Andrew G Chapple, Sydney McManus, Ann Byerley, Ethan Littlefield, Sarah Hemelt, John Lyons, Denise Danos, Omeed Moaven","doi":"10.1002/jso.70129","DOIUrl":"https://doi.org/10.1002/jso.70129","url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate potential disparities in multimodal treatment and its impact on outcomes among pancreatic cancer patients in Louisiana.</p><p><strong>Methods: </strong>Data on pancreatic cancer cases diagnosed between 2000 and 2020 were obtained from the Louisiana Tumor Registry. Bivariate relationships were assessed via Chi-square tests. Treatment was modeled with logistic regression models. Time-to-treatment was modeled with negative binomial regression models. Overall survival was analyzed with Cox proportional hazards models. Results are reported as odds ratio (OR), rate ratios (RR), hazards ratio (HR), and 95% Wald confidence intervals.</p><p><strong>Results: </strong>A total of 8,466 patients with pancreatic cancer were included. A significantly higher proportion of nonmetastatic cases received therapy compared to metastatic cases. Non-Hispanic Black patients with nonmetastatic disease experienced a significantly longer time to treatment compared to Non-Hispanic White patients. In the metastatic model, uninsured patients and those with Medicaid had the highest odds of not receiving therapy. Primary resection was a strong predictor of improved survival. Nonsurgical therapy also contributed to better outcomes.</p><p><strong>Conclusion: </strong>The findings of this study are instrumental in designing a more granular investigation of multi-level determinants to identify the actionable items driving the observed disparities associated with worse outcomes.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This retrospective study evaluated predictors of early versus late recurrence in 277 patients with oral squamous cell carcinoma (OSCC) who underwent surgical treatment between 2017 and 2020. Using receiver operating characteristic analysis, an 8-month disease-free survival cutoff effectively stratified patients into early (DFS < 8 months) and late (DFS ≥ 8 months) recurrence groups. Early recurrence was associated with significantly poorer overall survival (mean OS 24.03 months) compared to late recurrence (mean OS 35.26 months). Multivariate logistic regression identified adjuvant therapy status and type, bone involvement, positive pathological nodal stage, and perineural invasion as independent predictors of early recurrence. Local recurrences demonstrated better survival outcomes than regional or distant failures. The findings underscore the prognostic significance of recurrence timing and highlight the need for risk-adapted surveillance and tailored adjuvant strategies in high-risk OSCC patients.
{"title":"Predictors of Early Versus Late Recurrence in Post-Surgical Oral Cancer Patients.","authors":"Poonam Joshi, Labani Kole, Manasi Bavaskar, Arjun Singh, Rathan Shetty, Sudhir Nair, Pankaj Chaturvedi","doi":"10.1002/jso.70154","DOIUrl":"https://doi.org/10.1002/jso.70154","url":null,"abstract":"<p><p>This retrospective study evaluated predictors of early versus late recurrence in 277 patients with oral squamous cell carcinoma (OSCC) who underwent surgical treatment between 2017 and 2020. Using receiver operating characteristic analysis, an 8-month disease-free survival cutoff effectively stratified patients into early (DFS < 8 months) and late (DFS ≥ 8 months) recurrence groups. Early recurrence was associated with significantly poorer overall survival (mean OS 24.03 months) compared to late recurrence (mean OS 35.26 months). Multivariate logistic regression identified adjuvant therapy status and type, bone involvement, positive pathological nodal stage, and perineural invasion as independent predictors of early recurrence. Local recurrences demonstrated better survival outcomes than regional or distant failures. The findings underscore the prognostic significance of recurrence timing and highlight the need for risk-adapted surveillance and tailored adjuvant strategies in high-risk OSCC patients.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonio J Esgueva, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Maria Joao Cardoso, Kwok Leung Cheung, Jakob De Vries, Peter van Dam, Isabel T Rubio
Introduction: Sentinel lymph node biopsy (SLNB) after neoadjuvant treatment (NAT) is an increasing option for axillary surgery in patients responding to treatment, whether diagnosed as clinically node-negative (cN0) or node-positive (cN + ). This study evaluates SLNB trends in patients with NAT in a large European population.
Materials and methods: Data sourced from EUSOMADB, collating prospectively collected data from certified European Breast Units, included 17,321 patients who have undergone NAT between 2010 and 2021. Of those, 9,226 and 8.095 are clinically N0 and cN1, respectively.
Results: During the study period, for cN0 patients, there has been a significant increase in the proportion of cases with SLNB, rising from 86% in the 2010-2015 period to 94% in the 2016-2021 period. Consequently, a decline in direct axillary dissection (AD) has been shown in both periods, dropping from 14% to 6% (p < 0.001). Similarly, in cN+ patients, SLNB increased from 25% to 40%, while direct AD decreased from 75% to 60% (p < 0.001). Regarding immunohistochemistry subtypes, higher SLNB rates were reported in triple-negative and HER2-enriched tumors. Nevertheless, SLNB rates rose significantly across all immunohistochemical subtypes (p < 0.001) between both periods. Multivariate analysis identified as statistically significant predictors of SLNB: surgery period (second period), molecular subtype (HER2-positive, triple-negative), breast-conserving surgery and type of NAT.
Conclusion: This study evidences a substantial shift towards SLNB as the primary axillary surgery following NAT during the study period. This trend emphasizes a preference for less invasive procedures, likely due to the efficacy of neoadjuvant therapy in reducing axillary lymph node involvement.
{"title":"Changing Practices in Axillary Surgery After Neoadjuvant Breast Cancer Therapy: Insights From the EUSOMA European Database.","authors":"Antonio J Esgueva, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Maria Joao Cardoso, Kwok Leung Cheung, Jakob De Vries, Peter van Dam, Isabel T Rubio","doi":"10.1002/jso.70158","DOIUrl":"https://doi.org/10.1002/jso.70158","url":null,"abstract":"<p><strong>Introduction: </strong>Sentinel lymph node biopsy (SLNB) after neoadjuvant treatment (NAT) is an increasing option for axillary surgery in patients responding to treatment, whether diagnosed as clinically node-negative (cN0) or node-positive (cN + ). This study evaluates SLNB trends in patients with NAT in a large European population.</p><p><strong>Materials and methods: </strong>Data sourced from EUSOMADB, collating prospectively collected data from certified European Breast Units, included 17,321 patients who have undergone NAT between 2010 and 2021. Of those, 9,226 and 8.095 are clinically N0 and cN1, respectively.</p><p><strong>Results: </strong>During the study period, for cN0 patients, there has been a significant increase in the proportion of cases with SLNB, rising from 86% in the 2010-2015 period to 94% in the 2016-2021 period. Consequently, a decline in direct axillary dissection (AD) has been shown in both periods, dropping from 14% to 6% (p < 0.001). Similarly, in cN+ patients, SLNB increased from 25% to 40%, while direct AD decreased from 75% to 60% (p < 0.001). Regarding immunohistochemistry subtypes, higher SLNB rates were reported in triple-negative and HER2-enriched tumors. Nevertheless, SLNB rates rose significantly across all immunohistochemical subtypes (p < 0.001) between both periods. Multivariate analysis identified as statistically significant predictors of SLNB: surgery period (second period), molecular subtype (HER2-positive, triple-negative), breast-conserving surgery and type of NAT.</p><p><strong>Conclusion: </strong>This study evidences a substantial shift towards SLNB as the primary axillary surgery following NAT during the study period. This trend emphasizes a preference for less invasive procedures, likely due to the efficacy of neoadjuvant therapy in reducing axillary lymph node involvement.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charbel Chidiac, Caitlyn Ramdat, Katherine M McDermott, Adam S Levin, Kathryn M Lemberg, Daniel S Rhee
Objective: Extraskeletal Ewing sarcoma (EES) is a variant of Ewing sarcoma that originates from soft tissues rather than bones. Our study aims to characterize the differences between EES and skeletal ES (SES) in the pediatric population.
Methods: We conducted a retrospective review of children ≤ 18 years with ES recorded in the National Cancer Data Base (NCDB) from 2004 to 2022. Kaplan-Meier curves and Cox proportional hazards regression analysis were used to identify risk factors associated with survival.
Results: Among 7446 identified patients, 1016 (20.9%) had EES and 6430 (79.1%) had SES. EES patients were older (median 14 vs. 13 years, p = 0.007), more often female (46.9% vs. 41.2%, p = 0.0009), and had smaller tumors (7.5 vs. 8.0 cm, p = 0.003). Tumor distribution differed significantly, with EES was most frequent in the thorax (49.8%) and head and neck (11.8%), while SES more common in the lower limbs (30.2%) and pelvis (25.3%) (p < 0.0001). EES patients were more likely to receive surgery alone (4.2% vs. 1.8%) or a combination of surgery, chemotherapy, and radiation (25.9% vs. 20.7%) but less likely to receive chemotherapy and radiation without surgery (19.4% vs. 29.3%, p < 0.05). Five-year overall survival was similar between SES (72.2%) and EES (73.7%) (p = 0.70). Multivariable analysis confirmed EES was not an independent predictor of survival (aHR 0.94; 95% CI 0.81-1.10). Factors independently associated with mortality were older age, metastasis at diagnosis, and positive surgical margins.
Conclusions: Demographic, treatment characteristics, and prognostic factors differ between pediatric patients with SES and EES. However, survival is similar between the two groups.
目的:骨外尤文氏肉瘤(EES)是尤文氏肉瘤的一种变体,起源于软组织而非骨骼。我们的研究旨在描述EES和骨骼ES (SES)在儿科人群中的差异。方法:我们对2004年至2022年国家癌症数据库(NCDB)中记录的≤18岁ES儿童进行了回顾性研究。Kaplan-Meier曲线和Cox比例风险回归分析用于确定与生存相关的危险因素。结果:7446例患者中,EES 1016例(20.9%),SES 6430例(79.1%)。EES患者年龄较大(中位年龄14岁vs. 13岁,p = 0.007),多为女性(46.9% vs. 41.2%, p = 0.0009),肿瘤较小(7.5 cm vs. 8.0 cm, p = 0.003)。肿瘤分布差异显著,EES最常见于胸腔(49.8%)和头颈部(11.8%),而SES多见于下肢(30.2%)和骨盆(25.3%)(p)。结论:小儿SES和EES患者的人口学、治疗特点和预后因素存在差异。然而,两组患者的生存率相似。
{"title":"Comparison of Presentation and Management in Skeletal and Extraskeletal Ewing Sarcoma in Children.","authors":"Charbel Chidiac, Caitlyn Ramdat, Katherine M McDermott, Adam S Levin, Kathryn M Lemberg, Daniel S Rhee","doi":"10.1002/jso.70153","DOIUrl":"https://doi.org/10.1002/jso.70153","url":null,"abstract":"<p><strong>Objective: </strong>Extraskeletal Ewing sarcoma (EES) is a variant of Ewing sarcoma that originates from soft tissues rather than bones. Our study aims to characterize the differences between EES and skeletal ES (SES) in the pediatric population.</p><p><strong>Methods: </strong>We conducted a retrospective review of children ≤ 18 years with ES recorded in the National Cancer Data Base (NCDB) from 2004 to 2022. Kaplan-Meier curves and Cox proportional hazards regression analysis were used to identify risk factors associated with survival.</p><p><strong>Results: </strong>Among 7446 identified patients, 1016 (20.9%) had EES and 6430 (79.1%) had SES. EES patients were older (median 14 vs. 13 years, p = 0.007), more often female (46.9% vs. 41.2%, p = 0.0009), and had smaller tumors (7.5 vs. 8.0 cm, p = 0.003). Tumor distribution differed significantly, with EES was most frequent in the thorax (49.8%) and head and neck (11.8%), while SES more common in the lower limbs (30.2%) and pelvis (25.3%) (p < 0.0001). EES patients were more likely to receive surgery alone (4.2% vs. 1.8%) or a combination of surgery, chemotherapy, and radiation (25.9% vs. 20.7%) but less likely to receive chemotherapy and radiation without surgery (19.4% vs. 29.3%, p < 0.05). Five-year overall survival was similar between SES (72.2%) and EES (73.7%) (p = 0.70). Multivariable analysis confirmed EES was not an independent predictor of survival (aHR 0.94; 95% CI 0.81-1.10). Factors independently associated with mortality were older age, metastasis at diagnosis, and positive surgical margins.</p><p><strong>Conclusions: </strong>Demographic, treatment characteristics, and prognostic factors differ between pediatric patients with SES and EES. However, survival is similar between the two groups.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}